EP Edge Journal Watch 36: ESC 2026, AF Ablation and Sham Trials | PVI-SHAM-AF, PFA-SHAM, SHAM-PVI, FlexPulse, NEXAF, IDEAL-AF, ENRICH-AF

What defines successful atrial fibrillation ablation: fewer recurrences, lower AF burden, better quality of life, or all three? In this ESC Congress 2026 special issue of EP Edge Journal Watch, Dr. Sharma examines evidence from Munich, Germany, August 28–31, 2026, alongside previously covered sham-controlled trials to explore what meaningful patient benefit should look like.PVI-SHAM-AF leads the discussion. Rolf Wachter and colleagues found lower sampled atrial fibrillation burden after catheter ablation, but no demonstrated superiority over sham on the primary Atrial Fibrillation Effect on Quality-of-Life (AFEQT) endpoint. We examine the primary result, the favorable sensitivity analysis, and why failure to demonstrate superiority does not establish equivalence.PFA-SHAM and SHAM-PVI provide the earlier evidence. These trials demonstrated additional patient-reported benefit with pulsed field ablation and cryoballoon pulmonary vein isolation, respectively. Their differing populations, endpoint priorities, and monitoring methods help frame the comparison, without implying that one ablation technology is superior to another.Our In Depth synthesis examines baseline symptom severity, possible ceiling effects, recruitment, cardioversion, antiarrhythmic management, beta blockers, and continuous versus intermittent rhythm monitoring. These are potential contributors to the discordant findings, not established explanations. Drawing on Andrea Natale’s review, the Marrouche–Glotzer editorial, and Dulai’s SHAM-PVI substudy, we distinguish rhythm recurrence from residual burden, symptoms, functional improvement, and treatment burden. What should count as clinical success, and which definitions still need prospective validation?FlexPulse follows with 12-month results for focal dual-energy radiofrequency and pulsed field ablation. We review 74.6% composite effectiveness, safety, redo-mapping findings, and the substantial effect of monitoring intensity on apparent success. Single-arm results and retrospective lesion-quality associations are not comparative proof.NEXAF examines structured exercise in AF care. A supervised-to-home exercise program reduced continuously monitored AF burden by 45% relative to usual care, but did not demonstrate superiority on the quality-of-life co-primary endpoint.IDEAL-AF evaluates individualized low-voltage substrate ablation in selected patients with persistent AF. We discuss improved rhythm outcomes beyond pulmonary vein isolation, patient selection, verified electrical endpoints, and the accompanying Kistler–Chieng editorial. The findings do not justify routine additional lesions in every patient.ENRICH-AF closes with edoxaban after intracranial hemorrhage. Fewer ischemic strokes were accompanied by more hemorrhagic strokes and major bleeding, without demonstrated superiority on the primary stroke or systemic embolism endpoint.NEXAF and ENRICH-AF are discussed as congress-results reports, not full results manuscripts. Designed for electrophysiologists, cardiologists, trainees, researchers, and cardiovascular care teams, this episode connects trial interpretation with patient counseling, medication review, and shared decision-making.Explore the complete newsletter, infographics, and references, and follow EP Edge Journal Watch for weekly electrophysiology analysis.